138 related articles for article (PubMed ID: 9575338)
21. Intramuscular immunization with plasmid coexpressing tumour antigen and Flt-3L results in potent tumour regression.
Fong CL; Mok CL; Hui KM
Gene Ther; 2006 Feb; 13(3):245-56. PubMed ID: 16163376
[TBL] [Abstract][Full Text] [Related]
22. Immune privilege and FasL: two ways to inactivate effector cytotoxic T lymphocytes by FasL-expressing cells.
Li JH; Rosen D; Sondel P; Berke G
Immunology; 2002 Mar; 105(3):267-77. PubMed ID: 11918688
[TBL] [Abstract][Full Text] [Related]
23. EBAG9 tempers lymphocyte killing activity.
Ménasché G; de Saint Basile G
J Clin Invest; 2009 Aug; 119(8):2136-40. PubMed ID: 19620775
[TBL] [Abstract][Full Text] [Related]
24. Incomplete tolerance to the tumour-associated antigen MDM2.
Ramírez F; Ghani Y; Stauss H
Int Immunol; 2004 Feb; 16(2):327-34. PubMed ID: 14734618
[TBL] [Abstract][Full Text] [Related]
25. Heat shock cognate protein 70 encodes antigenic epitopes recognised by HLA-B4601-restricted cytotoxic T lymphocytes from cancer patients.
Azuma K; Shichijo S; Takedatsu H; Komatsu N; Sawamizu H; Itoh K
Br J Cancer; 2003 Sep; 89(6):1079-85. PubMed ID: 12966429
[TBL] [Abstract][Full Text] [Related]
26. A calcium optimum for cytotoxic T lymphocyte and natural killer cell cytotoxicity.
Zhou X; Friedmann KS; Lyrmann H; Zhou Y; Schoppmeyer R; Knörck A; Mang S; Hoxha C; Angenendt A; Backes CS; Mangerich C; Zhao R; Cappello S; Schwär G; Hässig C; Neef M; Bufe B; Zufall F; Kruse K; Niemeyer BA; Lis A; Qu B; Kummerow C; Schwarz EC; Hoth M
J Physiol; 2018 Jul; 596(14):2681-2698. PubMed ID: 29368348
[TBL] [Abstract][Full Text] [Related]
27. Lessons from T cell responses to virus induced tumours for cancer eradication in general.
Melief CJ; Kast WM
Cancer Surv; 1992; 13():81-99. PubMed ID: 1423326
[TBL] [Abstract][Full Text] [Related]
28. Targeted calcium influx boosts cytotoxic T lymphocyte function in the tumour microenvironment.
Kim KD; Bae S; Capece T; Nedelkovska H; de Rubio RG; Smrcka AV; Jun CD; Jung W; Park B; Kim TI; Kim M
Nat Commun; 2017 May; 8():15365. PubMed ID: 28504276
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms of Antiviral Cytotoxic CD4 T Cell Differentiation.
Knudson CJ; Férez M; Alves-Peixoto P; Erkes DA; Melo-Silva CR; Tang L; Snyder CM; Sigal LJ
J Virol; 2021 Sep; 95(19):e0056621. PubMed ID: 34260270
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of in vivo generation of cytotoxic effector cells against tumor in tumor-bearing mice.
Fuyama S; Yamamoto H; Fujii Y; Arai S
Cancer Res; 1986 Nov; 46(11):5548-52. PubMed ID: 2428480
[TBL] [Abstract][Full Text] [Related]
31. A novel approach to the induction of specific cytolytic T cells in vivo.
Ley V; Roth C; Langlade-Demoyen P; Larsson-Sciard EL; Kourilsky P
Res Immunol; 1990; 141(9):855-63. PubMed ID: 2100017
[TBL] [Abstract][Full Text] [Related]
32. Small cell lung carcinomas express shared and private tumor antigens presented by HLA-A1 or HLA-A2.
Yamazaki K; Spruill G; Rhoderick J; Spielman J; Savaraj N; Podack ER
Cancer Res; 1999 Sep; 59(18):4642-50. PubMed ID: 10493519
[TBL] [Abstract][Full Text] [Related]
33. Differential requirements of CD4(+) T-cell signals for effector cytotoxic T-lymphocyte (CTL) priming and functional memory CTL development at higher CD8(+) T-cell precursor frequency.
Umeshappa CS; Nanjundappa RH; Xie Y; Freywald A; Xu Q; Xiang J
Immunology; 2013 Apr; 138(4):298-306. PubMed ID: 23113741
[TBL] [Abstract][Full Text] [Related]
34. Enhancement of effector CD8+ T-cell function by tumour-associated B7-H3 and modulation of its counter-receptor triggering receptor expressed on myeloid cell-like transcript 2 at tumour sites.
Kobori H; Hashiguchi M; Piao J; Kato M; Ritprajak P; Azuma M
Immunology; 2010 Jul; 130(3):363-73. PubMed ID: 20141543
[TBL] [Abstract][Full Text] [Related]
35. Delivery of foreign cytotoxic T lymphocyte epitopes to tumor tissues for effective antitumor immunotherapy against pre-established solid tumors in mice.
Kavunja HW; Lang S; Sungsuwan S; Yin Z; Huang X
Cancer Immunol Immunother; 2017 Apr; 66(4):451-460. PubMed ID: 28011995
[TBL] [Abstract][Full Text] [Related]
36. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells.
Schmidt SM; Schag K; Müller MR; Weck MM; Appel S; Kanz L; Grünebach F; Brossart P
Blood; 2003 Jul; 102(2):571-6. PubMed ID: 12576330
[TBL] [Abstract][Full Text] [Related]
37. RPE cells resist bystander killing by CTLs, but are highly susceptible to antigen-dependent CTL killing.
Gregerson DS; Lew KL; McPherson SW; Heuss ND; Ferrington DA
Invest Ophthalmol Vis Sci; 2006 Dec; 47(12):5385-94. PubMed ID: 17122128
[TBL] [Abstract][Full Text] [Related]
38. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells.
Tsai V; Southwood S; Sidney J; Sakaguchi K; Kawakami Y; Appella E; Sette A; Celis E
J Immunol; 1997 Feb; 158(4):1796-802. PubMed ID: 9029118
[TBL] [Abstract][Full Text] [Related]
39. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
40. Does antibody-dependent epitope masking permit progressive tumour growth in the face of cell-mediated cytotoxicity?
Manson LA
Immunol Today; 1991 Oct; 12(10):352-5. PubMed ID: 1720318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
